Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension: The AQUARIUS Randomized Clinical Trial
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Blood pressure reduction and renin-angiotensin-aldosterone system inhibition are targets for treatment of atherosclerosis. The effect of renin inhibition on coronary disease progression has not been investigated. OBJECTIVE: To determine the effects of renin inhibition with aliskiren on progression of coronary atherosclerosis. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial (Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study) comparing aliskiren with placebo in 613 participants with coronary artery disease, systolic blood pressure between 125 and 139 mm Hg (prehypertension range), and 2 additional cardiovascular risk factors conducted at 103 academic and community hospitals in Europe, Australia, and North and South America (enrollment from March 2009 to February 2011; end of follow-up: January 31, 2013). INTERVENTIONS: Participants underwent coronary intravascular ultrasound (IVUS) imaging and were randomized to receive 300 mg of aliskiren (n = 305) or placebo (n = 308) taken orally daily for 104 weeks. Disease progression was measured by repeat IVUS examination after at least 72 weeks of treatment. MAIN OUTCOMES AND MEASURES: The primary efficacy parameter was the change in percent atheroma volume (PAV) from baseline to study completion. Secondary efficacy parameters included the change in normalized total atheroma volume (TAV) and the percentage of participants with atheroma regression. Safety and tolerability were also assessed. RESULTS: Evaluable imaging data were available at baseline and follow-up for 458 participants (74.7%). The primary IVUS efficacy parameter, PAV, did not differ between participants treated with aliskiren (-0.33%; 95% CI, -0.68% to 0.02%) and placebo (0.11%; 95% CI, -0.24% to 0.45%) (between-group difference, -0.43% [95% CI, -0.92% to 0.05%]; P = .08). The secondary IVUS efficacy parameter, TAV, did not differ between participants treated with aliskiren (-4.1 mm3; 95% CI, -6.27 to -1.94 mm3) and placebo (-2.1 mm3; 95% CI, -4.21 to 0.07 mm3) (between-group difference, -2.04 mm3 [95% CI, -5.03 to 0.95 mm3]; P = .18). There were no significant differences in the proportion of participants who demonstrated regression of PAV (56.9% vs 48.9%; P = .08) and TAV (64.4% vs 57.5%; P = .13) in the aliskiren and placebo groups, respectively. CONCLUSIONS AND RELEVANCE: Among participants with prehypertension and coronary artery disease, the use of aliskiren compared with placebo did not result in improvement or slowing of progression of coronary atherosclerosis. These findings do not support the use of aliskiren for regression or prevention of progression of coronary atherosclerosis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00853827.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Self-citationNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Self-citationCardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Self-citationNicholls, S. J., Hsu, A., Wolski, K., Hu, B., Bayturan, O., Lavoie, A., Uno, K., Tuzcu, E. M., & Nissen, S. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.026 · Cited by 475
Self-citation
Cited by
Impact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression
Puri, R., Nicholls, S. J., Shao, M., Kataoka, Y., Uno, K., Kapadia, S. R., Tuzcu, E. M., & Nissen, S. E. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.036 · Cited by 571
Self-citationPuri, R., Nissen, S. E., Shao, M., Elshazly, M. B., Kataoka, Y., Kapadia, S. R., Tuzcu, E. M., & Nicholls, S. J. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307601 · Cited by 143
Self-citationElshazly, M. B., Mani, P., Nissen, S., Brennan, D. M., Clark, D., Martin, S., Jones, S. R., Quispe, R., Donnellan, E., Nicholls, S. J., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319887578 · Cited by 103
Self-citationBlood pressure lowering efficacy of renin inhibitors for primary hypertension
Musini, V. M., Lawrence, K. A., Fortin, P. M., Bassett, K., & Wright, J. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007066.pub3 · Cited by 98
Andrews, J., Janssan, A., Nguyen, T., Pisaniello, A. D., Scherer, D. J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K., Schwartz, G. G., et al. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.01.01 · Cited by 53
Self-citation
Metadata
- Authors
- Nicholls, S. J., Bakris, G. L., Kastelein, J. J. P., Menon, V., Williams, B., Armbrecht, J., Brunel, P., Nicolaides, M., Hsu, A., Hu, B., Fang, H., Puri, R., Uno, K., Kataoka, Y., Bash, D., & Nissen, S. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-09-18
- Volume
- 310
- Issue
- 11
- Pages
- 1135
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2143360708
- Cited by
- 74
- References
- 5
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension: The AQUARIUS Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2013.277169
- The paper
- Nicholls, S. J., Bakris, G. L., Kastelein, J. J. P., Menon, V., Williams, B., Armbrecht, J., Brunel, P., Nicolaides, M., Hsu, A., Hu, B., Fang, H., Puri, R., Uno, K., Kataoka, Y., Bash, D., & Nissen, S. E. (2013). Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension: The AQUARIUS Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2013.277169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.